Evaluation of three anorexiants. Clortermine hydrochloride (voranil), fenfluramine hydrochloride (pondimin), and mazindol (sanorex).
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001067:Appetite Depressants / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003863:Depression / Q000139:chemically induced; D004038:Diet, Reducing; D004341:Drug Evaluation; D005260:Female; D005277:Fenfluramine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009325:Nausea / Q000139:chemically induced; D009765:Obesity / Q000188:drug therapy*; D010627:Phenethylamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D013375:Substance Withdrawal Syndrome; D019966:Substance-Related Disorders; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D001067:Appetite Depressants; D007093:Imidazoles; D007211:Indoles; D010627:Phenethylamines; D010919:Placebos; D005277:Fenfluramine